Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations.
BACKGROUND
Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs.


OBJECTIVE
To assess whether control of hyperadrenocorticism (HAC) affects the concentrations of Hp, CRP, SAA, alkaline phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used to assess control of HAC following trilostane treatment, and whether a combination of these tests offers a valid method of assessing disease control.


METHODS
Hp, CRP, SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before and after treatment with trilostane. Adequate control of HAC was defined as post-ACTH cortisol less than 150 nmol/l.


RESULTS
Significant reductions in Hp, ALKP, cholesterol and SAA (P<0.05) but not of CRP were found after control of HAC. Only Hp, cholesterol and ALKP were moderately informative (Se & Sp>0.7) of disease control when compared to adrenocorticotropin or corticotropin (ACTH) stimulation test. SAA and CRP were unhelpful (Se & Sp<0.7). The analysis of the combination of the analytes did not improve the correlation with ACTH stimulation test.


CONCLUSIONS
Relying on these analytes does not provide additional information over ACTH stimulation test results when assessing control of HAC treated with trilostane.
Arteaga
A
A
Faculty of Veterinary Medicine, University of Glasgow, Glasgow, UK.
Dhand
N K
NK
McCann
T
T
Knottenbelt
C M
CM
Tebb
A J
AJ
Evans
H
H
Eckersall
P David
PD
Ramsey
I K
IK
D000209:Acute-Phase Proteins / Q000032:analysis / Q000378:metabolism*; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy*; D004285:Dogs; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006242:Haptoglobins / Q000378:metabolism; D006929:Hyperaldosteronism / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D000685:Serum Amyloid A Protein / Q000378:metabolism; D016896:Treatment Outcome
D000209:Acute-Phase Proteins; D015415:Biomarkers; D004791:Enzyme Inhibitors; D006242:Haptoglobins; D000685:Serum Amyloid A Protein; D013196:Dihydrotestosterone; D002097:C-Reactive Protein; D000469:Alkaline Phosphatase; C009954:trilostane